The historical rank and industry rank for Joinn Laboratories (China) Co's EV-to-EBIT or its related term are showing as below:
SHSE:603127'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.92 Med: 50.26 Max: 4532.23
Current: 3387.88
During the past 12 years, the highest EV-to-EBIT of Joinn Laboratories (China) Co was 4532.23. The lowest was 9.92. And the median was 50.26.
SHSE:603127's EV-to-EBIT is ranked worse than 100% of 103
companies
in the Medical Diagnostics & Research industry
Industry Median: 21.9
vs SHSE:603127: 3387.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Joinn Laboratories (China) Co's EV-to-EBIT
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's EV-to-EBIT falls into.
Joinn Laboratories (China) Co EV-to-EBIT Calculation
Joinn Laboratories (China) Co's current Enterprise Value is ¥7,678 Mil.
Joinn Laboratories (China) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joinn Laboratories (China) Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥10,315 Mil.
Joinn Laboratories (China) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co (SHSE:603127) Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603127 has been successfully added to your 